PE
Patrick G Enright (Director) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in Vera Therapeutics, Inc. (VERA). Across 2 priced purchase filings, the average 21-session return was +16.0% from execution and +12.4% from disclosure (delay-adjusted; derived). The largest single filing was $18.3M of MANE (1,075,000 sh across 2 lots, as filed), executed Feb 5. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+16.0%
avg across 2 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+12.4%
same 2 filings, from disclosure
Filings, ttm
2
2 buys · 0 sells
Median delay
2d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$18.5M
shares × price, as filed
Last traded
Feb 5
Filed Feb 5
Median ADV $64.6M across their filed names
Impact on $10,000 · 12M
$13,470 (+34.7%)
S&P 500 $10,907 (+9.1%) · 25.6 pts ahead
Patrick G Enright
S&P 500
Derived: compounded across filings from disclosure dates · past 12 months
Open performance→Volume by month
Buys $26.1M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 12 months
Most traded names
VERA
Vera Therapeutics, Inc.
VERA · 2 buys · 0 sells
2 filings
MANERecent filings
MANEPURCHASE
Veradermics, Incorporated
View filing →
$18.3M1,075,000 sh across 2 lots
Exec Feb 5
Filed Feb 5 · 7:03 PM ET VERAPURCHASE Vera Therapeutics, Inc. View filing → $250K
5,882 sh × $42.50
Exec Dec 11 2025
Filed Dec 15 2025 · 8:07 PM ET ZBIOPURCHASE Zenas BioPharma, Inc. View filing → $2.3M
117,255 sh across 2 lots
Exec Oct 9 2025
Filed Oct 14 2025 · 8:59 AM ET VERAPURCHASE Vera Therapeutics, Inc. View filing → $5.3M
250,000 sh across 4 lots
Exec Jun 23 2025
Filed Jun 25 2025 · 5:30 PM ET